210 related articles for article (PubMed ID: 32628819)
1. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
Jamieson C; Hasserjian R; Gotlib J; Cortes J; Stone R; Talpaz M; Thiele J; Rodig S; Pozdnyakova O
J Transl Med; 2015 Sep; 13():294. PubMed ID: 26357842
[TBL] [Abstract][Full Text] [Related]
3. Significance of bone marrow fibrosis in multiple myeloma.
Subramanian R; Basu D; Dutta TK
Pathology; 2007 Oct; 39(5):512-5. PubMed ID: 17886102
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bone marrow fibrosis in diffuse large B-cell lymphoma.
Cetintepe T; Ozkan G; Kucukzeybek BP; Cetintepe L; Unal DK; Solmaz S; Aygun K; Acar AG; Bener S; Çallı AO; Payzın KB
Int J Lab Hematol; 2024 Jun; 46(3):523-530. PubMed ID: 38361314
[TBL] [Abstract][Full Text] [Related]
6. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
7. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
10. Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
Sun C; Ye JN; Mao JJ; Ma KW; Zhou X
Oncol Res Treat; 2020; 43(11):592-604. PubMed ID: 33045715
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies for multiple myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
[No Abstract] [Full Text] [Related]
14. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
[TBL] [Abstract][Full Text] [Related]
15. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
16. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
[TBL] [Abstract][Full Text] [Related]
17. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Majithia N; Vincent Rajkumar S; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
Am J Hematol; 2015 Nov; 90(11):981-5. PubMed ID: 26214732
[TBL] [Abstract][Full Text] [Related]
20. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
